BACKGROUND: In European axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) clinical registries, we aimed to investigate commonalities and differences in (1) set-up, clinical data collection; (2) data availability and completeness; and (3) wording, recall period, and scale used for selected patient-reported outcome measures (PROMs). METHODS: Data was obtained as part of the EuroSpA Research Collaboration Network and consisted of (1) an online survey and follow-up interview, (2) upload of real-world data, and (3) selected PROMs included in the online survey. RESULTS: Fifteen registries participated, contributing 33,948 patients (axSpA: 21,330 (63%), PsA: 12,618 (37%)). The reported coverage of eligible patients ranged from 0.5 to 100%. Information on age, sex, biological/targeted synthetic disease-modifying anti-rheumatic drug treatment, disease duration, and C-reactive protein was available in all registries with data completeness between 85% and 100%. All PROMs (Bath Ankylosing Spondylitis Disease Activity and Functional Indices, Health Assessment Questionnaire, and patient global, pain and fatigue assessments) were more complete after 2015 (68-86%) compared to prior (50-79%). Patient global, pain and fatigue assessments showed heterogeneity between registries in terms of wording, recall periods, and scale. CONCLUSION: Important heterogeneity in registry design and data collection across fifteen European axSpA and PsA registries was observed. Several core measures were widely available, and an increase in data completeness of PROMs in recent years was identified. This study might serve as a basis for examining how differences in data collection across registries may impact the results of collaborative research in the future.

Aberdeen Centre for Arthritis and Musculoskeletal Health University of Aberdeen Aberdeen UK

Center for Rheumatic Diseases University of Medicine and Pharmacy Bucharest Romania

Center for Rheumatology and Spine Diseases DANBIO Registry Rigshospitalet Glostrup Denmark

Center for Treatment of Rheumatic and Musculoskeletal Diseases Diakonhjemmet Hospital Oslo Norway

Clinical Epidemiology Division Department of Medicine Solna Karolinska Institutet Stockholm Sweden

Copenhagen Center for Arthritis Research Rigshospitalet Glostrup Denmark

Department of Clinical Immunology and Rheumatology Amsterdam Medical Center Amsterdam Netherlands

Department of Rheumatology 1st Faculty of Medicine Charles University Prague Czech Republic

Department of Rheumatology Aarhus University Hospital Aarhus Denmark

Department of Rheumatology East Tallinn Central Hospital Tallinn Estonia

Department of Rheumatology Geneva University Hospital Geneva Switzerland

Department of Rheumatology Hospital Garcia de Orta Almada Lisbon Portugal

Department of Rheumatology Hospital General Universitario Gregorio Marañón Madrid Spain

Department of Rheumatology University Hospital Zurich University of Zurich Zurich Switzerland

Department of Rheumatology University Medical Centre Ljubljana Ljubljana Slovenia

Departments of Medicine and Rheumatology Helsinki University Hospital Helsinki Finland

Faculty of Health Sciences University of Eastern Finland Jyvaskyla Finland

Faculty of Medicine University of Iceland Reykjavik Iceland

Rheumatology Unit Department of Medicine University of Padova Padova Italy

Rheumatology Unit University of Bari Bari Italy

Sociedade Portuguesa de Reumatologia Reuma pt Lisbon Portugal

Universidad de La Laguna and Rheumatology Service La Laguna Spain

Zobrazit více v PubMed

Lapadula G, Ferraccioli G, Ferri C, et al. GISEA: an Italian biological agents registry in rheumatology. Reumatismo. 2011;63:155–64. PubMed

Codreanu C, Mogosan C, Enache L, et al. Romanian registry of rheumatic diseases: Efficacy and safety of biologic therapy in rheumatoid arthritis. Ann Rheum Dis. 2015;74(Issue Suppl 2). 10.1136/annrheumdis-2015-eular.5823.

Canhão H, Faustino A, Martins F, et al. Reuma. PT - the rheumatic diseases Portuguese register. Acta Reumatol Port. 2011;36:45–56. PubMed

Konttinen L, Honkanen V, Uotila T, et al. Biological treatment in rheumatic diseases: Results from a longitudinal surveillance: adverse events. Rheumatol Int. 2006;26:916–22. PubMed

Ciurea A, Scherer A, Weber U, et al. Age at symptom onset in ankylosing spondylitis: is there a gender difference? Ann Rheum Dis. 2014;73:1908–10. PubMed

Van Vollenhoven RF, Ashling J. Rheumatoid arthritis registries in Sweden. Clin Exp Rheumatol. 2005;23:195–200. PubMed

Pavelka K, Forejtová Š, Štolfa J, et al. Anti-TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRA. Clin Exp Rheumatol. 2009;27:958–63. PubMed

Carmona L, de la Vega M, Ranza R, et al. BIOBADASER, BIOBADAMERICA, and BIOBADADERM: Safety registers sharing commonalities across diseases and countries. Clin Exp Rheumatol. 2014;32:163–7. PubMed

Rotar Z, Hočevar A, Rebolj Kodre A, et al. Retention of the second-line biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis failing one tumor necrosis factor alpha inhibitor: data from the BioRx.si registry. Clin Rheumatol. 2015;34:1787–93. PubMed

Macfarlane GJ, Barnish MS, Jones EA, et al. The British Society for Rheumatology Biologics Registers in Ankylosing Spondylitis (BSRBR-AS) study: Protocol for a prospective cohort study of the long-term safety and quality of life outcomes of biologic treatment. BMC Musculoskelet Disord. 2015;16:347. PubMed PMC

Ibfelt EH, Jensen DV, Hetland ML. The Danish nationwide clinical register for patients with rheumatoid arthritis: DANBIO. Clin Epidemiol. 2016;8:737–742. PubMed PMC

Glintborg B, Gudbjornsson B, Krogh NS, et al. Impact of different infliximab dose regimens on treatment response and drug survival in 462 patients with psoriatic arthritis: Results from the nationwide registries DANBIO and ICEBIO. Rheumatol (United Kingdom) 2014;53:2100–9. PubMed

Kvien TK, Heiberg MS, Lie E, et al. A Norwegian DMARD register: Prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic diseases. Clin Exp Rheumatol. 2005;23:188–94. PubMed

Ørnbjerg LM, Brahe CH, Askling J, et al. Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration. Ann Rheum Dis. 2019;78:1536–1544. PubMed

Brahe CH, Ørnbjerg LM, Jacobsson L, et al. Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment - Results from 12 countries in EuroSpA. Rheumatol (United Kingdom) 2020;59:1640–1650. PubMed

Radner H, Dixon W, Hyrich K, et al. Consistency and utility of data items across european rheumatoid arthritis clinical cohorts and registers. Arthritis Care Res. 2015;67:1219–1229. PubMed

Kearsley-Fleet L, Závada J, Hetland ML, et al. The EULAR Study Group for Registers and Observational Drug Studies: Comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers. Rheumatol (United Kingdom) 2015;54:1074–1079. PubMed

Hewlett S, Hehir M, Kirwan JR. Measuring fatigue in rheumatoid arthritis: A systematic review of scales in use. Arthritis Rheum. 2007;57:429–39. PubMed

Nikiphorou E, Radner H, Chatzidionysiou K, et al. Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature. Arthritis Res Ther. 2016;18:251. PubMed PMC

McGettigan P, Alonso Olmo C, Plueschke K, et al. Patient Registries: an Underused Resource for Medicines Evaluation: Operational proposals for increasing the use of patient registries in regulatory assessments. Drug Saf. 2019;42:1343–1351. PubMed PMC

Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377–81. PubMed PMC

Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Informatics. 2019;95:103208. PubMed PMC

Ørnbjerg LM, Linde L, Georgiadis S, et al. Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration. Semin Arthritis Rheum. 2022;56:152081. PubMed

Ørnbjerg LM, Rugbjerg K, Georgiadis S, et al. One-Third of European Patients with Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment. J Rheumatol. 2022; 10.3899/jrheum.220459. Online ahead of print. PubMed

Šléglová O, Dušek L, Olejárová M, et al. Evaluation of status and quality of life in patients with ankylosing spondylitis - Validation of Czech versions of Bath questionnaires - BAS-G. BADAI a BASFI. Ces Revmatol. 2004;12:43–54.

Pedersen OB, Hansen GO, Svendsen AJ, et al. Adaptation of the Bath measures on disease activity and function in ankylosing spondylitis into Danish. Scand J Rheumatol. 2007;36:22–7. PubMed

Heikkilä S, Viitanen JV, Kautianen H, et al. Evaluation of the Finnish versions of the functional indices BASFI and DFI in spondylarthropathy. Clin Rheumatol. 2000;19:464–9. PubMed

Pimentel-Santos FM, Pinto T, Santos H, et al. Portuguese version of the bath indexes for ankylosing spondylitis patients: a cross-cultural adaptation and validation. Clin Rheumatol. 2012;31:341–6. PubMed

Cardiel MH, Londoño JD, Gutiérrez E, et al. Translation, cross-cultural adaptation, and validation of the Bath Ankylosing Spondylitis Functional Index (BASFI), the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Dougados Functonal Index (DFI) in a Spanish speaking population wit. Clin Exp Rheumatol. 2003;21:451–8. PubMed

Cronstedt H, Waldner A, Stenström CH. The Swedish version of the Bath Ankylosing Spondylitis Functional Index. Reliability and validity. Scand J Rheumatol Suppl. 1999;111:1–9. PubMed

Waldner A, Cronstedt H, Stenström CH. The Swedish version of the Bath Ankylosing Spondylitis Disease Activity Index. Reliability and validity. Scand J Rheumatol Suppl. 1999;111:10–16. PubMed

Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: The bath ankylosing spondylitis disease activity index. J Rheumatol. 1994;21:2286–91. PubMed

Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: The development of the bath ankylosing spondylitis functional index. J Rheumatol. 1994;21:2281–5. PubMed

Lindström U, Di Giuseppe D, Delcoigne B, et al. Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration. Ann Rheum Dis. 2021;80:1410–1418. PubMed PMC

Michelsen B, Lindström U, Codreanu C, et al. Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration. RMD Open. 2020;6:e001280. PubMed PMC

Lindqvist E, Olofsson T, Jöud A, et al. How good is the agreement between clinical diagnoses and classification criteria fulfilment in axial spondyloarthritis? Results from the SPARTAKUS cohort. Scand J Rheumatol. 2022; 10.1080/03009742.2022.2064183. Online ahead of print. PubMed

Cheung PP, De Wit M, Bingham CO, et al. Recommendations for the Involvement of Patient Research Partners (PRP) in OMERACT Working Groups. A Report from the OMERACT 2014 Working Group on PRP. J Rheumatol. 2016;43:187–93. PubMed

De Wit MPT, Berlo SE, Aanerud GJ, et al. European League Against Rheumatism recommendations for the inclusion of patient representatives in scientific projects. Ann Rheum Dis. 2011;70:722–6. PubMed

Glintborg B, Jensen DV, Terslev L, et al. Nationwide, large-scale implementation of an online system for remote entry of patient-reported outcomes in rheumatology: characteristics of users and non-users and time to first entry. RMD Open. 2022;8:e002549. PubMed PMC

Boers M, Tugwell P, Felson DT, et al. World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol Suppl. 1994;41:86–9. PubMed

van der Heijde D, Bellamy N, Calin A, et al. Preliminary core sets for endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group. J Rheumatol. 1997;24:2225–9. PubMed

Van Der Heijde D, Calin A, Dougados M, et al. Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. J Rheumatol. 1999;26:951–4. PubMed

Dean LE, MacFarlane GJ, Jones GT. Five potentially modifiable factors predict poor quality of life in ankylosing spondylitis: results from the scotland registry for ankylosing spondylitis. J Rheumatol. 2018;45:62–9. PubMed

Sousa VD, Rojjanasrirat W. Translation, adaptation and validation of instruments or scales for use in cross-cultural health care research: a clear and user-friendly guideline. J Eval Clin Pract. 2011;17(2):268–74. PubMed

Challenge of missing data in observational studies: investigating cross-sectional imputation methods for assessing disease activity in axial spondyloarthritis

Differences in the response to TNF inhibitors at distinct joint locations in patients with psoriatic arthritis: results from nine European registries

Recording of non-musculoskeletal manifestations, comorbidities and safety outcomes in European spondyloarthritis registries: a survey

Impact of patient characteristics on ASDAS disease activity state cut-offs in axial spondyloarthritis: results from nine European rheumatology registries